Market Cap: $105B
GP
GSK plc
GSK
NYSE (New York Stock Exchange)USD
Market Cap: $105B
GSK Plc (Ticker: GSK) makes significant strides in addressing unmet medical needs for patients with pyelonephritis, a challenging kidney infection. The focus on innovative treatment pathways underscor…
On June 10, 2026, GSK Plc (Ticker: GSK) announces its strategic acquisition of Nuvalent, Inc., a clinical-stage precision oncology firm, for $10.6 billion. This acquisition exemplifies GSK's commitmen…
U.S. Government’s Vaccine Advisory Panel Actions Under Legal Scrutiny A federal court's recent commentary on the U.S. government's handling of vaccine recommendations signals a significant development…
GSK Expands Prescription Offerings, Enhancing Accessibility for Consumers GSK Plc makes significant strides in expanding its portfolio of discounted prescription medications, increasing the total numb…
GSK Expands Prescription Offerings to Enhance Accessibility and Affordability GSK Plc is poised to make significant advancements in the realm of affordable healthcare with its recent decision to expan…
### GSK’s Pioneering Step in Pediatric Respiratory Care On Friday, GSK plc achieves a major milestone in respiratory health when the U.S. Food and Drug Administration (FDA) expands the approved age in…
GSK’s Expanded Efforts Against RSV: A Significant Regulatory Milestone The recent approval by the U.S. Food and Drug Administration (FDA) to expand the age indication for GSK plc's respiratory syncyti…
GSK Settles Class Action Over BOOSTRIX Marketing Practices GSK Plc has recently reached a settlement in a class action lawsuit that revolves around allegations concerning the misleading advertising of…
Settlement Announcement Marks New Chapter for GSK Plc Amid BOOSTRIX Controversy GSK Plc finds itself navigating a significant legal development as the company agrees to a class action settlement regar…
GSK’s Anticipated Growth Amid Market Fluctuations GSK Plc, a leading player in the global pharmaceuticals industry, focuses heavily on research and development, aiming to bring innovative therapies to…
GSK's Strategic Focus on Long-Term Growth Initiatives GSK Plc is actively advancing its strategy in the biopharmaceutical sector, positioning itself to fortify its long-term growth trajectory. The com…
GSK Plc's Strategic Focus on Long-term Growth Potential in Pharma Innovations GSK Plc continues to concentrate its efforts on delivering innovative pharmaceutical solutions, catering to unmet medical…
GSK's Strategic Move to Enhance Therapeutic Pipeline through Licensing Agreement with Frontier Biotechnologies In a pivotal step towards expanding its biopharmaceutical capabilities, GSK Plc signs an…
GSK Advances siRNA Drug Development Through Partnership with Frontier Biotechnologies GSK Plc solidifies its commitment to innovative biopharmaceutical solutions through a newly announced exclusive li…
Frontier Biotech and GSK Forge Strategic Alliance in siRNA Therapeutics Frontier Biotechnologies Inc. recently announces an exclusive licensing agreement with GSK, establishing a notable partnership i…
GSK’s communications face a recurring problem when source excerpts omit the company name Communications teams at GSK and across the pharmaceutical sector regularly confront a practical obstacle: summa…
GSK and JAX‑NYSCF set five‑year plan to humanise neurodegeneration research GSK Plc is entering a five‑year strategic research collaboration with the Jackson Laboratory–New York Stem Cell Foundation C…
GSK and JAX‑NYSCF form five‑year alliance to model Alzheimer’s in human cells Building scalable, patient-derived cellular platforms to speed translation GSK announces a strategic, five‑year research c…
AI for Law Firms Forces a Re‑Think in Pharma Compliance and M&A for GSK Anthropic’s new program for smaller law firms prompts a rapid reassessment across industries, and pharmaceutical groups such as…
GSK Confronts AI-driven Shake-up in Pharma Legal and Funding Landscape AI's immediate pressure on lawyers, funders and drug development Pharmaceutical giant GSK faces a near-term industry shake-up as…
Securing Minerals, Protecting Medicines: What the U.S. Conference Means for GSK The U.S. State Department is hosting miners from 50 countries this week as Washington and Brussels push to strengthen st…
GSK and Helix Forge Strategic Alliance to Advance Genomic Research In a significant development for GSK Plc, the global biopharmaceutical company announces a multi-year strategic collaboration with He…
Strategic Collaboration Positions GSK at the Forefront of Genomic Research In a significant development within the biopharmaceutical sector, GSK Plc has entered into a multi-year strategic collaborati…
GSK's Strategic Leap into Genomic Research with Helix Collaboration GSK Plc is making significant strides in its research and development efforts by entering into a multi-year strategic collaboration…
GSK Faces Pricing Pressure Amid Industry-Wide Drug Hikes In a significant development for the pharmaceutical sector, drugmakers, including GSK Plc, are poised to implement price increases on over 350…